Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01872533 · ClinicalTrials.gov registry record · Early Phase 1

Effect of 10-day Overnight Hypoxia Treatment on Whole Body Insulin Sensitivity (SLEEP HIGH Study)

A Early Phase 1 study of Insulin Resistance, sponsored by Pennington Biomedical Research Center.

Completed
Registry status
Early Phase 1
Development phase
9
Enrollment target
1
Study location

NCT01872533 is a Early Phase 1 study of Insulin Resistance that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 9 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01872533, a Early Phase 1 study of Insulin Resistance, has completed, sponsored by Pennington Biomedical Research Center.

COMPLETED
Registry status
Early Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to look at how a reduction in oxygen levels (hypoxia) influences insulin sensitivity and carbohydrate metabolism. It is expected that 10 nights of exposure to moderate hypoxia (\~ 15% O2, similar to conditions at an altitude of \~7500 feet) will improve glucose metabolism.

Conditions Studied

Interventions

  • OTHER Hypoxia Exposure

Study Locations (1)

Louisiana

  • Pennington Biomedical Research Center - Baton Rouge

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2011-07
Est. Completion 2013-05
Phase Early Phase 1

What the Registry Record Tells You About NCT01872533

The ClinicalTrials.gov registry entry for NCT01872533 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (96% lower). The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which Hypoxia Exposure is the first listed.

NCT01872533 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.

Frequently Asked Questions

What is clinical trial NCT01872533 about?

NCT01872533 is a clinical study titled "Effect of 10-day Overnight Hypoxia Treatment on Whole Body Insulin Sensitivity (SLEEP HIGH Study)". The purpose of this study is to look at how a reduction in oxygen levels (hypoxia) influences insulin sensitivity and carbohydrate metabolism. It is expected that 10 nights of exposure to moderate hypoxia (\~ 15% O2, similar to conditions at an altitude of \~7500 feet) will improve glucose metabolis...

What is the current status of trial NCT01872533?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2011-07. Estimated completion is 2013-05.

What conditions does trial NCT01872533 study?

This clinical trial studies the following conditions: Insulin Resistance.

What interventions are being tested in trial NCT01872533?

The interventions under investigation include: Hypoxia Exposure (OTHER).

Who is sponsoring clinical trial NCT01872533?

This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01872533 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.